
Novo Nordisk to sue over Hims & Hers Wegovy copy
Novo Nordisk said it will take legal and regulatory action against telehealth provider Hims & Hers after it unveiled a cheaper copycat Wegovy. Hims plans an oral semaglutide pill priced at $49 for the first month and $99 thereafter under a 5-month plan, triggering about 7% declines in Novo Nordisk and Eli Lilly shares; Novo argues the product is illegal mass compounding that risks patient safety, while Hims says its copy uses a different formulation. Wegovy’s SNAC absorption technology is a key point of contrast, and Lilly is preparing its own oral GLP-1, orforglipron, pending FDA approval.













